Market Intelligence, Clinical Progress, and High-Purity Reagents for Complement Lectin Pathway Inhibition.
Protein Structure & Key Mutations
MASP1 (Mannan-binding lectin serine protease 1) is a key initiator of the complement lectin pathway. The full-length protein consists of six domains: CUB1, EGF-like (calcium-binding), CUB2, CCP1, CCP2, and a serine protease (SP) domain (UniProt P48740). Critical functional domains include:
- CUB1 (amino acid region 1–133)
- EGF-like; calcium-binding (134–176)
- CUB2 (177–311)
Clinically relevant mutations associated with the 3MC1 syndrome and other disorders are documented:
- 3MC1 variant (UniProt VAR_078814)
- dbSNP rs1062049 (UniProt VAR_051831)
- Another 3MC1 mutation (UniProt VAR_090500)
High-purity recombinant proteins covering these domains are essential for structural studies, epitope mapping, and selectivity screening.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MASP1 drug discovery. Select the right modality for your research stage:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-length) | MASP1 Recombinant Protein (CUB-EGF-CUB-CCP-CCP-SP); >95% purity, <1EU/ug endotoxin. Sequence verified. | View MASP1 Products |
| Antigen (Catalytic Domain) | MASP1 Recombinant Catalytic Domain for enzymatic activity assays; high activity and stability. | View MASP1 Products |
| Mutant Control | MASP1 S654A Catalytic Mutant; active site serine to alanine for mechanism studies and negative controls. | View MASP1 Products |
| Ortholog Panel | Human/Mouse/Cynomolgus MASP1 proteins; expressed in HEK293 for cross-reactivity testing. | View MASP1 Products |
| Gene Delivery | MASP1 Promise-ORF / Lentivirus; full-length ORF for stable cell line construction. | View MASP1 Products |
| Benchmark Antibody | Anti-MASP1 Benchmark Antibody; recombinant positive control for assay standardization. | View MASP1 Products |
| Validator (siRNA) | MASP1 siRNA Set; for specific knockdown verification in cell-based assays. | View MASP1 Products |
| Related Target A | MASP2 – crucial for lectin pathway specificity counter-screening. | View MASP2 Products |
| Related Target B | MBL2 – initiator complex partner for pathway reconstitution assays. | View MBL2 Products |
| Related Target C | C2 – downstream substrate for functional protease assays. | View C2 Products |
Critical Assay Challenges & TarMart Advantage
| Assay Challenge | TarMart Solution (Technical Spec) |
|---|---|
| Homolog Counter-Screening (MASP1 vs MASP2) | Human MASP1 and MASP2 proteins available with >95% purity and verified structural integrity. |
| Enzymatic Activity Preservation | Mammalian expression (HEK293) ensures native glycosylation and accurate folding. |
| Lack of Controls | Clinical Benchmark Antibodies included for assay standardization. |
| False Positives | Validated siRNA included for specificity checks in cell-based functional assays. |
| Low Selectivity of Small Molecules | Comprehensive panel of serine proteases (MASP2, MASP3, C1r, C1s, thrombin, FXa) for off-target testing. |
Global Clinical Landscape & Future Outlook
The race for MASP1 therapeutics is intensifying as the lectin pathway of the complement system becomes a major target for severe inflammatory and autoimmune conditions. With the success of downstream complement inhibitors (e.g., eculizumab targeting C5, ravulizumab), major players are shifting focus upstream to MASP1 and MASP2 to prevent cascade initiation without broadly suppressing immune function. First-generation therapies like Omeros’ narsoplimab (anti-MASP2) have reached the clinic, and the next wave targets highly selective monoclonal antibodies and small molecule inhibitors for indications such as IgA nephropathy, atypical hemolytic uremic syndrome (aHUS), and ischemia-reperfusion injury. Companies like Novartis and Roche are actively pursuing MASP1-selective small molecules, while RNAi approaches (Alnylam, Ionis) aim for sustained knockdown. The combination of MASP1 and MASP2 inhibition may offer maximal lectin pathway blockade.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Omeros (MASP2), Apellis (C3), Alexion (C5) | aHUS, IgA Nephropathy, PNH | Epitope mapping, selectivity vs MASP2 (require high-purity recombinant MASP1) |
| Small Molecule Inhibitors | Novartis, Roche, Sanofi | Systemic Lupus Erythematosus (SLE), Immune-complex diseases | Selectivity assay (need homolog panel: MASP1/2/3 and related proteases) |
| RNAi / Antisense | Alnylam, Ionis | Complement-mediated disorders, hepatic targets | Knockdown validation (need siRNA, benchmark Abs, and functional cell-based assays) |
| Gene Therapy | Spark, UniQure (early stage) | Monogenic complement disorders | Overexpression/knockout models require MASP1 ORF and mutant controls |
Live MASP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: